BDX Jan 2025 175.000 call
| Previous Close | 76.68 |
| Open | N/A |
| Bid | 89.60 |
| Ask | 94.30 |
| Strike | 175.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 76.68 - 76.68 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
Simply Wall St.Becton Dickinson (NYSE:BDX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Simply Wall St.
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)
Key Insights Becton Dickinson's estimated fair value is US$258 based on 2 Stage Free Cash Flow to Equity Current share...
ZacksBD's (BDX) Latest Product Launch to Boost Research Outcome
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
- Simply Wall St.
Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ZacksBD's (BDX) New FDA Approval to Improve MRSA Diagnostics
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
- Simply Wall St.
With 90% institutional ownership, Becton, Dickinson and Company (NYSE:BDX) is a favorite amongst the big guns
Key Insights Given the large stake in the stock by institutions, Becton Dickinson's stock price might be vulnerable to...
- Thomson Reuters StreetEvents
Q1 2023 Accelerate Diagnostics Inc Earnings Call
Q1 2023 Accelerate Diagnostics Inc Earnings Call
ZacksBD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.
Yahoo Finance VideoBecton Dickinson CEO: Q2 ‘was another quarter of exceeding expectations’
Becton, Dickinson and Company CEO and President Tom Polen joins Yahoo Finance Live to discuss company earnings, growth opportunities in the home test kit market, biotech drugs, strong demand in the weight loss market, and the outlook for Becton Dickinson.
ZacksBecton Dickinson (BDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Reuters
Becton Dickinson raises 2023 profit forecast as demand rebounds
Becton Dickinson and Co on Thursday raised its full-year profit forecast and beat estimates for the second-quarter results on strong demand for its drug delivery devices and surgical equipment. The medical device maker joins peers Stryker Corp and Abbott Laboratories, which have raised their full-year forecasts on the easing of staffing shortages and recovery in medical procedures volumes. Revenue in the life sciences segment, which sells diagnostic devices, fell 14.2% to $1.28 billion from a year earlier, as demand for its COVID-19 test kits slumped due to lower levels of infections.
- Simply Wall St.
Is Becton, Dickinson and Company's (NYSE:BDX) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Becton Dickinson's (NYSE:BDX) stock increased significantly by 6.7% over the...
ZacksBecton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4% and 3.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksBD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
ZacksHere's Why You Should Invest in Edwards Lifesciences (EW) Now
Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.
- Simply Wall St.
Calculating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Becton Dickinson fair value estimate is US$262 Becton...
ZacksZacks.com featured highlights include Becton, Dickinson, Raytheon Technologies and Palantir Technologies
Becton, Dickinson, Raytheon Technologies and Palantir Technologies are part of the Zacks Screen of the Week article.
ZacksBDX vs. WST: Which Stock Is the Better Value Option?
BDX vs. WST: Which Stock Is the Better Value Option?
ZacksBD's (BDX) New Launch to Result in Optimal IV Placement
BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.
- Simply Wall St.
11%of this Becton, Dickinson and Company (NYSE:BDX) insider's holdings were sold in the last year
Viewing insider transactions for Becton, Dickinson and Company's ( NYSE:BDX ) over the last year, we see that insiders...
ZacksIs Avanos Medical (AVNS) Outperforming Other Medical Stocks This Year?
Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
- Simply Wall St.
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
- Simply Wall St.
Becton, Dickinson and Company's (NYSE:BDX) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Becton Dickinson's (NYSE:BDX) stock up by 4.4% over the past month. As most would know, long-term fundamentals have a...
ZacksBDX or WST: Which Is the Better Value Stock Right Now?
BDX vs. WST: Which Stock Is the Better Value Option?
- Simply Wall St.
Shareholders in Becton Dickinson (NYSE:BDX) are in the red if they invested a year ago
It's easy to feel disappointed if you buy a stock that goes down. But sometimes a share price fall can have more to do...